TIDMAGY

RNS Number : 9019R

Allergy Therapeutics PLC

11 March 2016

11 March 2015

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Grant of Options under Long Term Incentive Plan

Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today confirms that certain performance conditions attaching to provisional awards ("Awards") made pursuant to the Company's Long Term Incentive Plan ("LTIP") for the three years ended 8 March 2015, details of which were announced on 15 May 2013, have been met. Consequently, Allergy Therapeutics has today granted certain of its directors low cost options ("Options") over the Company's ordinary shares of 0.1 pence each ("Ordinary Shares") in replacement for the Awards made under the LTIP as follows:

 
 Director              Number of       Total number    Total remaining 
                        Ordinary        of Ordinary     number of 
                        Shares over     Shares over     Ordinary 
                        which Options   which Options   Shares provisionally 
                        granted         granted         awarded under 
                                                        LTIPs 
 
 Manuel Llobet, 
  Chief Executive 
  Officer                 905,000        1,529,024           1,690,000 
 Ian Postlethwaite, 
  Finance Director        452,500         928,012             845,000

The Options have been granted in accordance with the LTIP rules and can be exercisable between 11 March 2016 and 11 March 2026 at an exercise price of 0.1p per Ordinary Share.

For further information please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton

allergytherapeutics@consilium-comms.com

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information please see www.allergytherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSFMGMFVMDGVZM

(END) Dow Jones Newswires

March 11, 2016 11:36 ET (16:36 GMT)

Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Allergy Therapeutics Charts.
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Allergy Therapeutics Charts.